Pituitary metastasis from lung adenocarcinoma presenting with panhypopituitarism

2021 ◽  
Author(s):  
Hannah Morris ◽  
Jonathan Golding ◽  
Fahad Ahmed
Neurosurgery ◽  
2018 ◽  
Vol 85 (4) ◽  
pp. E773-E778 ◽  
Author(s):  
Hong Yao ◽  
Weiwei Rui ◽  
Yong Zhang ◽  
Yanting Liu ◽  
Shaojian Lin ◽  
...  

Abstract BACKGROUND AND IMPORTANCE Metastasis to the pituitary gland is uncommon in patients with systemic disseminated cancer. Individual articles have reported cases of pituitary metastasis mimicking a prolactinoma, but no case of a prolactin-secreting tumor metastasizing to the pituitary mimicking a prolactinoma has been reported so far. CLINICAL PRESENTATION This article reports a 67-yr-old man with a recent onset of headaches, ophthalmoplegia, hypopituitarism, and hyperprolactinemia who was initially diagnosed with prolactinoma and given bromocriptine in the local hospital. Because of vomiting after taking drugs, he was transferred to our hospital for further diagnosis and treatment. Serum prolactin was elevated up to 1022 ng/mL, and pituitary magnetic resonance imaging revealed a 2.9 × 2.8 × 2.3 cm sellar mass with pituitary apoplexy, for which endoscopic transsphenoidal surgery was performed. Postoperative pathology and western blotting disclosed a prolactin-positive metastatic lung adenocarcinoma. Whole exome sequencing revealed a number of gene mutations including KRAS, PIK3CA, ALK, and CTNNB1. The patient died of deterioration of the lung disease 3 mo after the initial diagnosis. CONCLUSION To the best of our knowledge, this is the first report of a prolactin-secreting tumor metastasizing to the pituitary mimicking a prolactinoma as confirmed by both immunohistochemistry and western blot. Prolactin secretion is rare and elusive, and may associate with specified gene mutations.


2020 ◽  
Vol 21 ◽  
Author(s):  
Miki Watanabe ◽  
Junichi Yasuda ◽  
Kenji Ashida ◽  
Yuko Matsuo ◽  
Ayako Nagayama ◽  
...  

Author(s):  
Ana M Lopes ◽  
Josué Pereira ◽  
Isabel Ribeiro ◽  
Ana Martins da Silva ◽  
Henrique Queiroga ◽  
...  

Summary Pituitary metastasis (PM) can be the initial presentation of an otherwise unknown malignancy. As PM has no clinical or radiological pathognomonic features, diagnosis is challenging. The authors describe the case of a symptomatic PM that revealed a primary lung adenocarcinoma. A 62-year-old woman with multiple sclerosis and no history of malignancy, incidentally presented with a diffusely enlarged and homogeneously enhancing pituitary gland associated with stalk enlargement. Clinical and biochemical evaluation revealed anterior hypopituitarism and diabetes insipidus. Hypophysitis was considered the most likely diagnosis. However, rapid visual deterioration and pituitary growth raised the suspicion of metastatic involvement. A search for systemic malignancy was performed, and CT revealed a lung mass, which proved to be a lung adenocarcinoma. Accordingly, the patient was started on immunotherapy. Resection of the pituitary lesion was performed, and histopathology analysis revealed metastatic lung adenocarcinoma. Following surgery, the patient underwent radiotherapy. More than 2 years after PM detection, the patient shows a clinically relevant response to antineoplastic therapy and no evidence of PM recurrence. Learning points Although rare, metastatic involvement of the pituitary gland has been reported with increasing frequency during the last decades. Pituitary metastasis can be the initial presentation of an otherwise unknown malignancy and should be considered in the differential diagnosis of pituitary lesions, irrespective of a history of malignancy. The sudden onset and rapid progression of visual or endocrine dysfunction from a pituitary lesion should strongly raise the suspicion of metastatic disease. MRI features of pituitary metastasis can overlap with those of other pituitary lesions, including hypophysitis; however, rapid pituitary growth is highly suggestive of metastatic disease. Survival after pituitary metastasis detection has improved over time, encouraging individualized interventions directed to metastasis to improve quality of life and increase survival.


2020 ◽  
Vol 35 (1) ◽  
pp. 133-136
Author(s):  
Radhamani Rajakumar ◽  
◽  
Ijaz Hallaj Rahmatullah ◽  
Anilah Abdul Rahim

2015 ◽  
Vol 21 ◽  
pp. 156
Author(s):  
Halis Akturk ◽  
Kaniksha Desai ◽  
Ana Maria Chindris

2019 ◽  
Vol 25 ◽  
pp. 319-320
Author(s):  
Lourdes Rodriguez ◽  
Mary Baker ◽  
Daniel W Karakla ◽  
David Lieb

2009 ◽  
Vol 138 (1) ◽  
pp. 51-62 ◽  
Author(s):  
Don X. Nguyen ◽  
Anne C. Chiang ◽  
Xiang H.-F. Zhang ◽  
Juliet Y. Kim ◽  
Mark G. Kris ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document